Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. Q4 FY2025 earnings call
March 17, 2026 · fiscal period ended 2025-12
EPS · actual vs est
Revenue · actual vs est
Summary
Generated 2026-03-17
Management highlights
2025 was a major growth inflection point driven by positive data from CORAL and RIVER trials. Raised capital for next trials. Had a positive end of phase two meeting with FDA for IPF-related cough program. Plan to initiate phase three program for IPF-related cough with two pivotal trials, one in Q2 2025 with ~300 patients, another in H2 2025. Intend to submit meeting request and protocol for non-IPF-ILD-related chronic cough program, plan adaptive Phase IIb trial. Plan Phase IIb parallel arm dose-ranging trial for RCC. Upcoming Investor and Analyst Day on May 7th and active at ATS meeting.
Segment performance
No specific product segment financial performance details provided in terms of absolute figures and revenue contribution %
Guidance
Ended 2025 with ~$188 million in cash, cash equivalents, and marketable securities, providing runway into 2028 to provide top-line data in key clinical trials including Phase IIb in RCC, Phase IIb in non-IPF-ILD, and top-line data in 12-week pivotal Phase III in IPF-related chronic cough
Risks
Actual results may differ materially from forward-looking statements due to various factors including those in the risk factors section of the company's most recent annual report on Form 10-K
Q&A highlights
Q: Rana Ruiz asked about remaining Phase I studies and non-IPF ILD trial design.
A: Jim and Jen answered about label informative studies and design alignment with FDA.
Q: Judah Frommer asked about non-IPF ILD, one vs two trials, and refractory chronic cough.
A: Jen and Jim responded.
Q: Annabelle Samimi's team asked about cash runway and secondary endpoints.
A: Dave and Jim answered.
Q: Alexa Deamer asked about RCC dose and data sharing.
A: Jim responded.
Q: Needham's question about secondary endpoints and orphan drug.
A: Jim answered.
Q: Ryan Deschner's question about read-through and enrollment.
A: Farrell responded.
Q: Brandon Folks' question about Phase 3 timing and placebo effect.
A: Jen and Jim answered.
Q: Devanjana Chatterjee's question about recruitment and drug-drug interaction.
A: Jim answered.
Q: William Wood's question about ILD study inclusion and drug scheduling.
A: Jen and Jim answered.
Q: Kaveri Bowman's question about pre-specified analyses and patient population broadening.
A: Jim answered
Key numbers
Reported versus consensus
Earnings calendar feed
| Metric | Reported | Consensus | Delta | Prior year |
|---|---|---|---|---|
| EPS | $-0.06 | $-0.10 | +37.9% | $-0.11 |
| Revenue | — | — | — | — |
Transcript
March 17, 2026Full transcript unavailable for redistribution
The structured summary above covers the available call sections. Full transcript text is not included on this page.
Continue exploring
Prior quarters
This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.